Citius Oncology, Inc. (CTOR)

NCM – Real Time Price. Currency in USD

0.81

+0.08 (11.16%)

At close: Aug 12, 2026, 4:00 PM EDT

0.81

0.00 (0.00%)

After-hours: Aug 12, 2026, 4:10 PM EDT

12.08.2026

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

CRANFORD, N.J., Aug. 12, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that its Board of Directors voted to appoint Jonathan Peri, Ph.D.

05.08.2026

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

New institutional accounts ordering LYMPHIR increased 78% quarter over quarter LYMPHIR's near-universal payer coverage expands market access Initial cutaneous T-cell lymphoma (CTCL) market for LYMPHIR currently exceeds $400 million CRANFORD, N.J., Aug. 5, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today provided an update on the expanding base of institutions ordering LYMPHIR® (denileukin diftitox-cxdl) through wholesalers, continued formulary progress at priority U.S. treatment centers, and other key indicators supporting the product's commercial launch.

Videos

No Data

There is no data to display

Press releases

12.08.2026

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

05.08.2026

Citius Oncology, Inc. (CTOR)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Citius Oncology, Inc. (CTOR)

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

Videos

No Data

Press releases

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

Videos

No Data

Press releases

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

Search stocks

Citius Oncology, Inc. (CTOR)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Citius Oncology, Inc. (CTOR)

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

Videos

No Data

Press releases

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

Videos

No Data

Press releases

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment